Re: Feuerstein’s take on today’s ITMN-191 data
This is not one of Feuerstein’s better writing efforts! He baldy wants to conclude that ITMN-191 is inferior to Telaprevir, but he is forced to concede that, on an apples to apples basis, the ITMN-191 data are indeed better.
Unable to bash ITMN-191 for its efficacy, Feuerstein then resorts to telling us that Telaprevir has a first mover advantage. As if we didn’t know that already!
Write-ups such as this one make it easy for me to justify not subscribing to Feuerstein’s biotech newsletter.
Market Data 
Markets 
AI
